Source - RNS
RNS Number : 1103K
Mediclinic International plc
06 April 2018
 



Mediclinic International plc

(Incorporated in England and Wales)

Company Number 8338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

 

 

6 April 2018

 

 

Notification of Major Interest in Mediclinic International plc shares

 


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

MEDICLINIC INTERNATIONAL PLC

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)

Non-UK issuer


2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments


An event changing the breakdown of voting rights


Other (please specify):


3. Details of person subject to the notification obligation

Name

PUBLIC INVESTMENT CORPORATION SOC LIMITED

City and country of registered office (if applicable)

PRETORIA, SOUTH AFRICA

4. Full name of shareholder(s) (if different from 3.)

Name

N/A

City and country of registered office (if applicable)


5. Date on which the threshold was crossed or reached:

05/04/2018

6. Date on which issuer notified (DD/MM/YYYY):

06/04/2018

7. Total positions of person(s) subject to the notification obligation


% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

7.989%


7.989%

737 243 810

Position of previous notification (if

applicable)

8.064%


8.064%


 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rights

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)


58 894 769


7.989%












SUBTOTAL 8. A

58 894 769

7.989%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration
date

Exercise/
Conversion Period

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights


















SUBTOTAL 8. B 1

NIL

NIL

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration
date

Exercise/
Conversion Period

Physical or cash

settlement

Number of voting rights

% of voting rights






















SUBTOTAL 8.B.2

NIL

NIL

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer


Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
(please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

PUBLIC INVESTMENT CORPORATION SOC LIMITED

7.989%


7.989%


















10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A


11. Additional information

Name: DEVILLIERS MAKONKO

E-Mail: Devilliers.Makonko @pic.gov.za

TEL: +27 12 742 3578

 

 

Place of completion

PRETORIA, SOUTH AFRICA

Date of completion

06 April 2018

 

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

 

For further information please contact:

Mediclinic International plc

James Arnold, Head of Investor Relations

[email protected]

+44 (0)20 3786 8181

 

Company Secretary, Link Company Matters Limited

Victoria Dalby

+44 (0)207 954 9600

 

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com 

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUNOKRWVASRRR